منابع مشابه
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this ...
متن کاملFortune or failure: missed opportunities and chance discoveries in science
ALEXANDER KOHN, Fortune or failure: missed opportunities and chance discoveries in science, Oxford, Basil Blackwell, 1989, 8vo, pp. x, 199, illus., £14.95. Poor Aristotle: what opportunities he missed! If only he had applied that marvellous mind to making his ideas about motion more quantitative he would have spotted the contradiction in his ideas about falling bodies. Better still, he could ha...
متن کاملThe Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities.
Discovering the genetic basis of a Mendelian phenotype establishes a causal link between genotype and phenotype, making possible carrier and population screening and direct diagnosis. Such discoveries also contribute to our knowledge of gene function, gene regulation, development, and biological mechanisms that can be used for developing new therapeutics. As of February 2015, 2,937 genes underl...
متن کاملTranslating molecular discoveries into new therapies for atherosclerosis.
Atherosclerosis is characterized by the thickening of the arterial wall and is the primary cause of coronary artery disease and cerebrovascular disease, two of the most common causes of illness and death worldwide. Clinical trials have confirmed that certain lipoproteins and the renin-angiotensin-aldosterone system are important in the pathogenesis of atherosclerotic cardiovascular disease, and...
متن کاملS1P signaling: new therapies and opportunities
Development of sphingosine-1-phosphate receptor 1 (S1P1) modulators to dampen inflammation and its sequelae is becoming increasingly promising for treating medical conditions characterized by significant immunopathology. As shown by the non-selective S1P receptor modulator FTY720 (fingolimod [Gilenya(®)]) in the treatment of relapsing-remitting multiple sclerosis (MS), the ability to use S1P1 m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2014
ISSN: 1759-4812,1759-4820
DOI: 10.1038/nrurol.2014.262